Type-II Collagen
9 benefits mapped to clinical evidence across supplements.
Dose per serving from products
534 products in our catalogue print how much Type-II Collagen a serving holds.
Most common: 100 mg to 250 mg, 16% of 534 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 15 |
| 10 mg to 25 mg | 69 |
| 25 mg to 50 mg | 82 |
| 50 mg to 100 mg | 65 |
| 100 mg to 250 mg | 87 |
| 250 mg to 500 mg | 67 |
| 500 mg to 1 g | 32 |
| 1 g to 2.5 g | 35 |
| 2.5 g to 5 g | 36 |
| 5 g to 10 g | 32 |
| over 10 g | 14 |
Dose per serving from research
24 study groups in 17 studies say how much Type-II Collagen participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 25 mg to 50 mg, 21% of 24 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mcg or less | 2 |
| 50 mcg to 100 mcg | 3 |
| 100 mcg to 250 mcg | 0 |
| 250 mcg to 500 mcg | 2 |
| 500 mcg to 1 mg | 1 |
| 1 mg to 2.5 mg | 1 |
| 2.5 mg to 5 mg | 2 |
| 5 mg to 10 mg | 1 |
| 10 mg to 25 mg | 1 |
| 25 mg to 50 mg | 5 |
| 50 mg to 100 mg | 1 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 1 |
| 1 g to 2.5 g | 3 |
Commonly used together
7 of 24 study groups took Type-II Collagen with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Hyaluronic Acid | 5 |
| Collagen | 4 |
| Vitamin C | 4 |
| Chondroitin | 3 |
| Glucosamine | 3 |
Benefit Evidence
Pain/function ↑; relapse
Wound healing ↑ (~2x)
Cartilage marker ↓, pain ↓
Research sources
Joints & tendons (47)
- Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study
PubMed ID: 16145678
MRI changes correlated with CTX‑II shifts — links structural joint changes to CTX‑II biomarker.
- Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial
PubMed ID: 28549430
IA hyaluronic acid single injection reduced Coll2‑1 (a type II collagen degradation marker) vs placebo over 6 months, indicating reduced cartilage breakdown.
- A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis
PubMed ID: 28056936
In men, ch‑OSA reduced CTX‑II and COMP (cartilage degradation markers), indicating a cartilage‑protective signal in that subgroup.
- A Dietary Supplement in the Management of Patients with Lumbar Osteochondrosis: A Randomized, Double-Blinded, Placebo-Controlled Study
PubMed ID: 39203831
Supplement containing type‑II collagen increased lumbar intervertebral disc MRI volume significantly vs placebo (structural effect on cartilage/IVD).
- [Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D(3) and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint]
PubMed ID: 38785054
Artneo reduced MRI synovitis area (inflammation adjacent to cartilage) and improved stiffness—indirect support for cartilage environment improvement.
- Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
PubMed ID: 15380045
HRT in RA produced large CTX‑II reductions — direct evidence of reduced type‑II collagen breakdown.
- Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women
PubMed ID: 17010685
Strontium ranelate produced a consistent ~15–20% reduction in urinary CTX‑II, a validated marker of type‑II collagen degradation — strong support for cartilage collagen preservation.
- Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial
PubMed ID: 23881439
Alendronate reduced urinary CTX-II (type II collagen breakdown marker) in hip OA, showing effect on cartilage turnover.
- A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis
PubMed ID: 33687578
Low PRO‑C2 (type‑II collagen formation) predicts faster cartilage loss—biomarker evidence tying type‑II collagen biology to cartilage outcomes.
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
Undenatured type‑II collagen improved objective gait/pain in arthritic dogs, consistent with chondroprotective or symptomatic cartilage support.
- Novel Hydrolyzed Chicken Sternal Cartilage Extract Improves Facial Epidermis and Connective Tissue in Healthy Adult Females: A Randomized, Double-Blind, Placebo-Controlled Trial
PubMed ID: 31221944
Oral hydrolyzed chicken sternal cartilage (contains hydrolyzed collagen II) increased skin collagen and elasticity vs placebo, supporting benefits to connective tissues (cutaneous model).
- Effect of an oral preparation containing hyaluronic acid, chondroitin sulfate, hydrolyzed collagen type II and hydrolyzed keratin on synovial fluid features and clinical indices in knee osteoarthritis. A pilot study
PubMed ID: 33213125
Oral mix including hydrolyzed collagen II lowered synovial inflammatory cytokines and improved symptoms; suggests potential cartilage‑protective effects though multi‑ingredient.
- Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides
PubMed ID: 20436079
Observational study: increased CTX‑II and low type II collagen formation in early RA — informative for pathology and rationale for interventions targeting collagen II.
- Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products
PubMed ID: 12006327
Bisphosphonates in postmenopausal women halved urinary CTX‑II (type II collagen degradation), indicating the mechanistic importance of reducing type II collagen breakdown for cartilage support.
- Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor
PubMed ID: 12610815
Direct tissue data: a 3‑week MMP inhibitor increased proteoglycan synthesis marker and total type II collagen content in human OA cartilage, strongly linking interventions to cartilage matrix improvement.
- The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy
PubMed ID: 15542048
Estrogen regimens reduced urinary CTX‑II by ~19–30% — direct cartilage turnover evidence.
- Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM)
PubMed ID: 15356403
SERM produced ~50% suppression of urinary CTX‑II — substantial effect on type‑II collagen turnover.
- Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis
PubMed ID: 16128596
Nimesulide markedly reduced urinary CTX‑II — biomarker evidence of cartilage protection.
- Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis
PubMed ID: 16005273
Oral salmon calcitonin reduced urinary CTX‑II dose‑dependently — cartilage turnover effect.
- Pressure ulcer healing with a concentrated, fortified, collagen protein hydrolysate supplement: a randomized controlled trial
PubMed ID: 16557055
Oral collagen hydrolysate improved wound healing — direct evidence of supporting connective tissue repair.
- Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis
PubMed ID: 16753310
Observational data linking urinary type‑II neoepitope levels to joint space narrowing — supports the marker's relevance to cartilage health.
- Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
PubMed ID: 17009253
Oral salmon calcitonin lowered CTX‑II and C2C (type‑II collagen degradation markers) in knee OA — direct intervention evidence affecting cartilage turnover.
- Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study
PubMed ID: 17075851
Risedronate reduced a biochemical marker of type‑II collagen degradation though no clinical benefit was observed — biomarker-level cartilage effect.
- Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
PubMed ID: 17993283
Large risedronate trial lowered urinary CTX‑II (type II collagen degradation) and associated with less radiographic progression — direct cartilage-marker evidence.
- Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis
PubMed ID: 18785308
Adalimumab significantly decreased urinary CTX‑II in ankylosing spondylitis — shows therapy can reduce type II collagen breakdown.
- Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy
PubMed ID: 19813008
Relationship between oral salmon calcitonin exposure and CTX‑I suppression; supports dose‑exposure→biomarker effect concept relevant to cartilage markers in related studies.
- The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study
PubMed ID: 19747581
Oral salmon calcitonin produced statistically significant reductions in CTX‑II (type II collagen degradation marker) → biomarker evidence of reduced cartilage breakdown.
- Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone
PubMed ID: 20039425
Tocilizumab + methotrexate substantially reduced multiple cartilage turnover markers (including type II collagen peptides) in RA → strong evidence for reducing cartilage turnover.
- Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis
PubMed ID: 20525836
Baseline CTX‑II predicts long‑term radiographic progression in early RA → supports importance of reducing CTX‑II to protect cartilage long term.
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
PubMed ID: 20574648
Tocilizumab monotherapy slowed radiographic joint damage in biomarker‑defined high‑risk RA patients (including high uCTX‑II) → supports cartilage protection/maintenance.
- Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation
PubMed ID: 20565725
Oral salmon calcitonin suppressed urinary CTX‑II in short‑term PD study → supports modulation of cartilage degradation markers.
- Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis
PubMed ID: 20726814
Strontium ranelate reduced urinary CTX‑II in OA patients over months → pharmacologic evidence of reduced cartilage degradation (not a Type‑II collagen supplement but relevant biology).
- Inhalation therapy of calcitonin relieves osteoarthritis of the knee
PubMed ID: 23166425
Nasal calcitonin + exercise decreased urinary CTX-II significantly, indicating reduced type II collagen breakdown.
- A Multicenter Study of Early Anti-inflammatory Treatment in Patients With Acute Anterior Cruciate Ligament Tear
PubMed ID: 28146402
Early intra‑articular corticosteroid blunted the rise in synovial CTX‑II after ACL tear, suggesting short‑term cartilage preservation.
- Radiological and biochemical effects (CTX-II, MMP-3, 8, and 13) of low-level laser therapy (LLLT) in chronic osteoarthritis in Al-Kharj, Saudi Arabia
PubMed ID: 27913970
LLLT trial reported favorable changes in CTX‑II and MMPs alongside symptomatic improvement, indicating positive cartilage effects.
- Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study
PubMed ID: 26787505
Large RA biomarker subanalysis showed suppression of collagen degradation fragments (including C2M), reflecting modulation of connective tissue turnover.
- Knee Joint Distraction Compared with High Tibial Osteotomy and Total Knee Arthroplasty: Two-Year Clinical, Radiographic, and Biochemical Marker Outcomes of Two Randomized Controlled Trials
PubMed ID: 30758214
Knee joint distraction led to net type‑II collagen synthesis (PIIANP/CTX‑II shift) and JSW gains over 2 years, indicating cartilage repair/regeneration (surgical intervention).
- Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis
PubMed ID: 31481084
Large observational study showing uCTX‑II strongly associates with OA severity; supports the relevance of interventions that alter collagen II turnover for cartilage support (indirect).
- Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial
PubMed ID: 31887743
Trial with MIV‑711 reduced MRI bone and cartilage structural progression and lowered collagen turnover biomarkers (direct structural/cartilage support evidence).
- Changes in levels of cartilage oligomeric proteinase and urinary C-terminal telopeptide of type II collagen in subjects with knee osteoarthritis after dextrose prolotherapy: A randomized controlled trial
PubMed ID: 33904585
Dextrose prolotherapy reduced uCTX‑II (type‑II collagen breakdown marker) and improved symptoms, indicating reduced cartilage degradation.
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
Clinical improvement in pain/stiffness/function in RCT of hydrolyzed type‑II collagen suggests symptomatic cartilage benefit; biomarker/structural data not reported but symptomatic changes supportive.
- Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study
PubMed ID: 34737064
Sprifermin increased cartilage thickness (qMRI) and altered PRO‑C2, directly demonstrating cartilage structural support in responders.
- Comparison of clinical outcome, cartilage turnover, and inflammatory activity following either intra-articular or a combination of intra-articular with intra-osseous platelet-rich plasma injections in osteoarthritis knee: A randomized, clinical trial
PubMed ID: 36414504
PRP reduced urinary CTX‑II (type‑II collagen degradation marker) and improved clinical outcomes—shows cartilage biomarker modulation can accompany symptom benefit.
- Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
PubMed ID: 37446173
Direct biomarker evidence of reduced type‑II collagen breakdown (CTX‑II) over years in alkaptonuria, indicating healthier connective cartilage ECM.
- [Efficacy and safety of undenatured type II collagen in patients with knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 38829812
UC‑II improved clinical cartilage‑related outcomes in knee OA (WOMAC/KOOS); supports cartilage health.
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Bovine collagen peptides reduced urine CTX‑II (−30–34%), improved MRI MOAKS cartilage scores and WOMAC vs placebo — strong structural/cartilage support evidence.
- [Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 40237733
Artneo RCT reported improvements in imaging/clinical outcomes consistent with cartilage support.
Joint mobility (45)
- Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis
PubMed ID: 20726814
Strontium ranelate reduced CTX‑II long‑term, indicating a drug effect on cartilage breakdown over years (indirect evidence).
- NeoCart, an autologous cartilage tissue implant, compared with microfracture for treatment of distal femoral cartilage lesions: an FDA phase-II prospective, randomized clinical trial after two years
PubMed ID: 22637204
NeoCart patients had superior functional scores vs microfracture, consistent with better ROM in cartilage lesions.
- Effect of Mud-Bath Therapy on Serum Biomarkers in Patients with Knee Osteoarthritis: Results from a Randomized Controlled Trial
PubMed ID: 27228651
Mud‑bath therapy improved WOMAC subscores and function in knee OA, indicating better mobility.
- Radiological and biochemical effects (CTX-II, MMP-3, 8, and 13) of low-level laser therapy (LLLT) in chronic osteoarthritis in Al-Kharj, Saudi Arabia
PubMed ID: 27913970
Low‑level laser therapy reduced pain and had favorable cartilage biomarker changes with associated functional gains.
- Knee Joint Distraction Compared with High Tibial Osteotomy and Total Knee Arthroplasty: Two-Year Clinical, Radiographic, and Biochemical Marker Outcomes of Two Randomized Controlled Trials
PubMed ID: 30758214
Joint distraction produced net type‑II collagen synthesis and JSW increases at 2 years, indicating durable joint maintenance/repair (surgical model).
- Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis
PubMed ID: 31481084
uCTX‑II association with OA severity supports the idea that lowering collagen II breakdown is relevant to long‑term joint maintenance (observational).
- Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial
PubMed ID: 31887743
Pharmacologic agent reduced structural progression and collagen biomarkers — evidence supportive of strategies that maintain joint structure long‑term.
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
Robust improvements in pain, stiffness and function vs placebo imply subjectively easier movement in daily activities.
- Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study
PubMed ID: 34737064
Sprifermin produced durable cartilage thickness increases up to 104 weeks in biomarker‑stratified patients—direct long‑term structural evidence.
- UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study
PubMed ID: 35377244
Significant improvement in knee active flexion (primary reported ROM benefit) at 24 weeks.
- Efficacy and Safety of Dietary Undenatured Type II Collagen on Joint and Motor Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
PubMed ID: 35512781
NEXT‑II demonstrated consistent improvements in passive knee flexion across timepoints.
- Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions
PubMed ID: 36918892
HC‑II trial reported functional improvements (some muscle/mass gains) that could support mobility.
- Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
PubMed ID: 37446173
Multi‑year biomarker reductions in alkaptonuria (reduced CTX‑II) support long‑term preservation of cartilage collagen.
- [Efficacy and safety of undenatured type II collagen in patients with knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 38829812
Significant WOMAC/KOOS improvements indicate easier everyday movement for OA patients.
- Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study
PubMed ID: 39719905
Functional improvements (6MWT, BBS) suggest better range of motion.
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Biomarker (CTX‑II) reductions and MRI cartilage improvements indicate potential for long‑term maintenance of joint structure.
- The effect of supplementation with type I and type III collagen peptide and type II hydrolyzed collagen on pain, quality of life and physical function in patients with meniscopathy: a randomized, double-blind, placebo-controlled study
PubMed ID: 39755603
Meniscopathy trial showed large reductions in WOMAC pain and KOOS‑PS, translating to easier movement.
- [Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 40237733
Artneo KOOS improvements indicate better ROM and daily function.
- Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial
PubMed ID: 28549430
IAHA reduced Coll2‑1 for up to 6 months, indicating reduced cartilage degradation relevant to maintenance.
- A Dietary Supplement in the Management of Patients with Lumbar Osteochondrosis: A Randomized, Double-Blinded, Placebo-Controlled Study
PubMed ID: 39203831
Structural IVD volume gain suggests improved tissue resilience, though symptoms unchanged.
- [Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D(3) and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint]
PubMed ID: 38785054
Artneo participants had improvements in stiffness and function comparable to control, supporting mobility benefits.
- Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
PubMed ID: 15380045
Sustained CTX‑II and COMP reductions over 2 years in RA suggest maintained joint integrity.
- Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women
PubMed ID: 17010685
Reduction in CTX‑II suggests slowed cartilage collagen breakdown which could translate to greater joint resilience long term.
- A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis
PubMed ID: 33687578
PRO‑C2 low levels predict faster progression, informing long‑term maintenance strategies of cartilage via type‑II collagen biology.
- Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study
PubMed ID: 17204566
Chondroitin produced modest functional improvements (Lequesne/VAS) consistent with better mobility.
- Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial
PubMed ID: 19847319
UC‑II produced significant WOMAC functional improvements (improved mobility) vs glucosamine+chondroitin.
- Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study
PubMed ID: 21969261
Symptom/function scores improved in knee OA small trial, consistent with mobility gains.
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
Objective ground force plate improvements indicate improved mobility in dogs treated with UC‑II.
- Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
PubMed ID: 26604721
Demonstrated increases in normal walking speed and some functional improvements (knee-extensor strength, JKOM) — directly relevant to mobility.
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study
PubMed ID: 26822714
UC‑II RCT produced significant improvements in WOMAC total and functional Lequesne/ LFI scores, reflecting improved mobility and function.
- Effect of an oral preparation containing hyaluronic acid, chondroitin sulfate, hydrolyzed collagen type II and hydrolyzed keratin on synovial fluid features and clinical indices in knee osteoarthritis. A pilot study
PubMed ID: 33213125
Pilot RCT of a product containing hydrolyzed collagen II reported WOMAC/Lequesne improvements over 4 weeks (mobility/function gains).
- Effects of oral administration of type II collagen on rheumatoid arthritis
PubMed ID: 8378772
Observed reductions in swollen/tender joints and remissions imply easier movement for responders.
- Control of rheumatoid arthritis by oral tolerance
PubMed ID: 11592359
Significant improvement in DAS and higher responder rates in the 0.5 mg bovine CII group implies clinically meaningful improvements that commonly include mobility gains.
- Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products
PubMed ID: 12006327
Substantial CTX‑II reductions with bisphosphonates provide mechanistic evidence that long‑term cartilage degradation can be modulated (not by supplementation but relevant to the target biomarker).
- Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study
PubMed ID: 12428224
Baseline CTX‑II and CTX‑I strongly predicted radiographic progression over ~4 years, supporting the concept that modifying type II collagen turnover could affect long-term joint outcomes.
- The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy
PubMed ID: 15542048
Year‑long reductions in uCTX‑II support long‑term cartilage maintenance potential.
- Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM)
PubMed ID: 15356403
SERM normalized CTX‑II to premenopausal range — implies durable protection of cartilage matrix.
- Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study
PubMed ID: 16145678
Changes in MRI and CTX‑II over months show biomarker–structure coupling relevant to maintenance.
- Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis
PubMed ID: 16753310
uTIINE association with JSN supports the importance of modulating type‑II collagen turnover for long‑term structural outcomes.
- Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
PubMed ID: 17009253
Salmon calcitonin improved functional Lequesne scores in knee OA, indicating improved mobility/ease of movement.
- Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
PubMed ID: 17993283
Reduction in CTX‑II and less structural progression with risedronate suggests preserved cartilage integrity and resilience.
- A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis
PubMed ID: 19951408
Phase III CCII reduced pain and tender/swollen joint counts and improved function in RA (mobility-related outcomes).
- Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis
PubMed ID: 20525836
Baseline CTX‑II predicted 11‑year radiographic progression in early RA → supports targeting CTX‑II for long‑term maintenance.
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
PubMed ID: 20574648
Tocilizumab slowed radiographic progression over 1 year in biomarker‑high RA patients (including high uCTX‑II) → strong evidence for structural maintenance.
- Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation
PubMed ID: 20565725
Suppression of CTX‑II indicates reduced cartilage degradation that could contribute to greater joint resilience over time.
Joint comfort (31)
- [Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D(3) and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint]
PubMed ID: 38785054
Artneo reduced stiffness more than glucosamine+chondroitin and improved synovitis on MRI.
- Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial
PubMed ID: 23881439
Alendronate reduced hip OA pain (clinical improvement reported) though pharmacologic, not collagen supplement.
- Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study
PubMed ID: 17204566
Chondroitin sulfate produced modest, statistically significant pain/function improvements in knee OA (symptomatic relevance).
- Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial
PubMed ID: 19847319
UC-II RCT (knee OA) showed large reductions in WOMAC/VAS pain vs glucosamine+chondroitin.
- Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study
PubMed ID: 21969261
Small RCT supplement (glucosamine+chondroitin+quercetin) produced significant knee OA symptom improvements.
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
Undenatured type‑II collagen (UC‑II) in dogs produced objective gait improvements and reduced pain → strong translational signal for reduced joint pain/comfort.
- Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
PubMed ID: 26604721
Randomized multi-ingredient supplement containing 45 mg type II collagen peptides improved knee pain/function (JKOM) and walking speed in subgroups — supports symptomatic joint comfort though effect is confounded by other ingredients.
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study
PubMed ID: 26822714
Large RCT of undenatured type II collagen (UC-II) showed significant reductions in WOMAC pain and VAS pain vs placebo over 180 days.
- Effect of an oral preparation containing hyaluronic acid, chondroitin sulfate, hydrolyzed collagen type II and hydrolyzed keratin on synovial fluid features and clinical indices in knee osteoarthritis. A pilot study
PubMed ID: 33213125
Small RCT of a multi‑ingredient oral product containing hydrolyzed collagen II improved WOMAC/VAS pain and function but attribution to collagen II alone is uncertain.
- Effects of cartilage-supporting nutritional supplementation on knee osteoarthritis symptoms and quality of life in a 12-week randomized double-blind placebo-controlled pilot study
PubMed ID: 40664872
12‑week pilot RCT of a cartilage‑support supplement (contains type‑II collagen) showed modest WOMAC/KOOS symptom improvements.
- Effects of oral administration of type II collagen on rheumatoid arthritis
PubMed ID: 8378772
Randomized DB oral chicken type II collagen produced meaningful reductions in swollen/tender joints and some remissions → supports improved joint comfort.
- Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial
PubMed ID: 9485087
Large multicenter RCT showed a small but statistically significant clinical response at low dose (modest symptomatic benefit).
- Control of rheumatoid arthritis by oral tolerance
PubMed ID: 11592359
Randomized oral bovine type II collagen (0.5 mg) produced a small but statistically significant improvement in RA disease activity (DAS/ACR20), supporting symptomatic joint comfort.
- Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
PubMed ID: 17009253
Oral salmon calcitonin improved Lequesne (pain/function) in knee OA — directly supports symptomatic joint comfort.
- A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis
PubMed ID: 18576295
Smaller RA trial: chicken type II collagen produced clinically meaningful symptom improvements.
- Effects of AR7 Joint Complex on arthralgia for patients with osteoarthritis: results of a three-month study in Shanghai, China
PubMed ID: 18954461
AR7 (contains type II collagen) RCT reduced joint pain versus placebo over 3 months (multi-ingredient confounder).
- A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis
PubMed ID: 19951408
Large Phase III oral chicken type II collagen trial improved RA pain vs baseline (though inferior to MTX).
- Inhalation therapy of calcitonin relieves osteoarthritis of the knee
PubMed ID: 23166425
Nasal calcitonin + exercise improved knee OA pain scores and symptoms.
- Effect of Mud-Bath Therapy on Serum Biomarkers in Patients with Knee Osteoarthritis: Results from a Randomized Controlled Trial
PubMed ID: 27228651
Mud‑bath therapy trial produced clinically meaningful pain/function improvements in knee OA (symptomatic benefit).
- Radiological and biochemical effects (CTX-II, MMP-3, 8, and 13) of low-level laser therapy (LLLT) in chronic osteoarthritis in Al-Kharj, Saudi Arabia
PubMed ID: 27913970
Low‑level laser therapy RCT reduced knee pain in OA and improved cartilage‑related biomarkers.
- Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women
PubMed ID: 29497287
Eggshell membrane reduced recovery stiffness and exercise‑induced CTX‑II in short‑term trial.
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
Strong RCT evidence for symptom and function improvements supports enhanced overall joint wellbeing in treated participants.
- UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study
PubMed ID: 35377244
UC‑II RCT showed reduced activity‑related joint discomfort and improved knee flexion over 24 weeks.
- Efficacy and Safety of Dietary Undenatured Type II Collagen on Joint and Motor Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
PubMed ID: 35512781
NEXT‑II improved JKOM, VAS, and mobility tests reflecting everyday ease in joint tasks.
- Comparison of clinical outcome, cartilage turnover, and inflammatory activity following either intra-articular or a combination of intra-articular with intra-osseous platelet-rich plasma injections in osteoarthritis knee: A randomized, clinical trial
PubMed ID: 36414504
PRP trial reduced pain and KOOS vs saline; relevant as comparator evidence that cartilage/marker changes can coincide with symptom relief.
- Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions
PubMed ID: 36918892
HC‑II trial showed early (day‑14) pain reduction in knee OA patients versus baseline/placebo signals improved comfort.
- [Efficacy and safety of undenatured type II collagen in patients with knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 38829812
Multicenter RCT: oral undenatured chicken type‑II collagen produced significant WOMAC/VAS improvements vs placebo over 180 days.
- Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study
PubMed ID: 39719905
8‑week RCT of a supplement containing type‑II hydrolyzed collagen improved pain and QoL vs placebo (multi‑ingredient product).
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Substantial WOMAC improvements and reduced CTX‑II imply easier daily joint use.
- The effect of supplementation with type I and type III collagen peptide and type II hydrolyzed collagen on pain, quality of life and physical function in patients with meniscopathy: a randomized, double-blind, placebo-controlled study
PubMed ID: 39755603
8‑week RCT in meniscopathy (multi‑ingredient including 40 mg UC‑II) produced marked pain/QoL improvements.
- [Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 40237733
Randomized trial of Artneo (undenatured chicken UC‑II) showing significant reductions in pain (VAS/WOMAC) vs placebo.
Healthy aging (20)
- UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study
PubMed ID: 35377244
UC‑II improved knee function in symptomatic adults; this supports symptomatic management for aging joints though structural long‑term data are limited.
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Collagen peptides improved symptoms and cartilage biomarkers/MRI, supporting maintenance of aging joints.
- [Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 40237733
Artneo provided symptomatic and QoL improvements in knee OA, relevant to aging joints maintenance.
- Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis
PubMed ID: 20726814
Strontium ranelate reduced CTX‑II over 1–3 years in a large cohort → indicates potential to reduce cartilage breakdown in early/mild OA (aging joint context).
- Knee Joint Distraction Compared with High Tibial Osteotomy and Total Knee Arthroplasty: Two-Year Clinical, Radiographic, and Biochemical Marker Outcomes of Two Randomized Controlled Trials
PubMed ID: 30758214
Knee joint distraction in OA patients showed cartilage repair signals and durable symptom benefit, supporting structural approaches to aging joint care (surgical evidence).
- Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis
PubMed ID: 31481084
Large cross‑sectional study linking higher uCTX‑II with worse radiographic OA and pain in older adults highlights the importance of interventions targeting collagen II turnover for aging joints (indirect).
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
RCT in symptomatic adults produced meaningful short‑term improvements in pain, stiffness and function — relevant to symptomatic aging joints.
- Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study
PubMed ID: 34737064
Sprifermin produced cartilage thickness gains primarily among patients with low baseline PRO‑C2—relevant to targeted support in vulnerable (aging/progressive) joints.
- [Efficacy and safety of undenatured type II collagen in patients with knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 38829812
UC‑II RCT in knee OA demonstrates benefit in an older/degenerative joint population.
- Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
PubMed ID: 15380045
HRT reduced CTX‑II in RA/postmenopausal women — implies cartilage protection in aging joints.
- Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women
PubMed ID: 17010685
Strontium ranelate's sustained reduction in CTX‑II suggests a disease‑modifying effect relevant to aging cartilage preservation.
- Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial
PubMed ID: 23881439
Hip OA population (older adults) showed pain improvement and CTX-II reduction with alendronate; relevant to aging joints though pharmacologic.
- A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis
PubMed ID: 33687578
Low serum PRO‑C2 (type‑II collagen formation) associates with faster radiographic progression, implying relevance to aging joint deterioration risk.
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study
PubMed ID: 26822714
UC‑II RCT in knee OA (typical aging joint population) showed improved symptoms and function over 6 months, supporting aging joint care.
- Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products
PubMed ID: 12006327
Substantial reductions in CTX‑II with bisphosphonates indicate that lowering type II collagen degradation is feasible — relevant for protecting aging joints, though not supplementation data.
- The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy
PubMed ID: 15542048
Estrogen reduced CTX‑II in postmenopausal women — relevant for aging cartilage turnover.
- Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM)
PubMed ID: 15356403
SERM normalized CTX‑II to premenopausal range — relevant to postmenopausal/aging joint care.
- Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis
PubMed ID: 16753310
Higher urinary type‑II neoepitope linked to JSN — useful for understanding progression in aging joints.
- Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
PubMed ID: 17009253
Salmon calcitonin reduced type‑II degradation markers and improved function in OA — relevant to older joints with cartilage loss.
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
PubMed ID: 20574648
Tocilizumab reduced progression in biomarker‑high RA patients (including uCTX‑II) → supports long‑term structural protection relevant to aging joints.
Daily comfort (21)
- The effect of supplementation with type I and type III collagen peptide and type II hydrolyzed collagen on pain, quality of life and physical function in patients with meniscopathy: a randomized, double-blind, placebo-controlled study
PubMed ID: 39755603
Marked improvements in WOMAC, KOOS‑PS and SF‑12 suggest better daily activities in meniscopathy patients.
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
RCT showed large improvements in pain, stiffness and function (WOMAC) that directly translate into better ability to perform daily activities.
- Knee Joint Distraction Compared with High Tibial Osteotomy and Total Knee Arthroplasty: Two-Year Clinical, Radiographic, and Biochemical Marker Outcomes of Two Randomized Controlled Trials
PubMed ID: 30758214
Durable functional improvements after joint distraction suggest enhanced capacity for daily activities long‑term (surgical evidence).
- Effect of Mud-Bath Therapy on Serum Biomarkers in Patients with Knee Osteoarthritis: Results from a Randomized Controlled Trial
PubMed ID: 27228651
Mud‑bath therapy improved WOMAC subscores and VAS pain, which support everyday activity performance.
- NeoCart, an autologous cartilage tissue implant, compared with microfracture for treatment of distal femoral cartilage lesions: an FDA phase-II prospective, randomized clinical trial after two years
PubMed ID: 22637204
Improved IKDC/KOOS scores indicate better capacity for daily tasks after cartilage implant.
- A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis
PubMed ID: 19951408
CCII improved RA pain and function vs baseline, supporting daily activity performance in that patient group.
- Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
PubMed ID: 17009253
Function/pain improvements (Lequesne) translate directly into support for basic daily activities in knee OA.
- Control of rheumatoid arthritis by oral tolerance
PubMed ID: 11592359
Improved disease activity and responder status with bovine CII likely translates into better ability to perform daily activities for responders.
- Effects of oral administration of type II collagen on rheumatoid arthritis
PubMed ID: 8378772
Clinical improvements and remissions indicate responders could better perform daily activities.
- Effect of an oral preparation containing hyaluronic acid, chondroitin sulfate, hydrolyzed collagen type II and hydrolyzed keratin on synovial fluid features and clinical indices in knee osteoarthritis. A pilot study
PubMed ID: 33213125
Short pilot RCT reported functional gains consistent with improved capacity for daily tasks (multi‑ingredient product).
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Large symptom reductions and improved MRI/biomarker profile support improved daily activity performance.
- Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study
PubMed ID: 39719905
Functional and QoL improvements suggest support for daily activities with a type‑II collagen‑containing supplement.
- [Efficacy and safety of undenatured type II collagen in patients with knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 38829812
Significant KOOS/WOMAC improvements indicate improved capacity to perform daily activities after UC‑II supplementation.
- Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions
PubMed ID: 36918892
HC‑II reported improvements in pain and functional metrics that can aid daily activity performance.
- Efficacy and Safety of Dietary Undenatured Type II Collagen on Joint and Motor Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
PubMed ID: 35512781
NEXT‑II improved functional tests (walking, stair‑climb) and symptom scores important to daily activities.
- UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study
PubMed ID: 35377244
UC‑II improved ROM and reduced activity‑related discomfort relevant for routine tasks.
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study
PubMed ID: 26822714
UC‑II produced significant reductions in pain and improvements in functional indices (WOMAC, LFI), directly supporting daily activities.
- Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
PubMed ID: 26604721
Clear increases in walking speed and functional scores indicate enhanced capability for daily activities in some participants receiving the multi-ingredient supplement containing type II collagen peptides.
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
Functional gait improvements suggest greater ease with routine activities after UC‑II supplementation in dogs.
- Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial
PubMed ID: 19847319
UC‑II improved WOMAC function and VAS pain, outcomes directly relevant to daily living tasks in knee OA.
- Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study
PubMed ID: 17204566
Chondroitin's moderate symptomatic benefit supports daily activity performance for some patients.
Wellbeing (16)
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
Improved gait and reduced pain in arthritic dogs implies support for more active behavior with UC‑II supplementation.
- Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial
PubMed ID: 19847319
UC‑II reduced knee pain and improved function, supporting patients' ability to perform low‑impact activities more comfortably.
- The effect of supplementation with type I and type III collagen peptide and type II hydrolyzed collagen on pain, quality of life and physical function in patients with meniscopathy: a randomized, double-blind, placebo-controlled study
PubMed ID: 39755603
Large symptomatic and QoL gains in meniscopathy likely support increased activity tolerance.
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Marked symptom reduction and MRI/cartilage biomarker improvement that would enable more active lifestyle in OA patients.
- Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study
PubMed ID: 39719905
Improvements in 6MWT and balance tests indicate better capacity for activity.
- [Efficacy and safety of undenatured type II collagen in patients with knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]
PubMed ID: 38829812
UC‑II improved function and QoL in knee OA, supporting an active lifestyle.
- Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions
PubMed ID: 36918892
HC‑II combined with chicken essence improved lean mass/grip strength, supporting more active function.
- Efficacy and Safety of Dietary Undenatured Type II Collagen on Joint and Motor Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
PubMed ID: 35512781
NEXT‑II improved walking and stair‑climb performance, indicating support for low‑impact active behaviours.
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
Demonstrated reductions in pain/stiffness and improved function make low‑impact activity more achievable for symptomatic individuals.
- UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study
PubMed ID: 35377244
UC‑II reductions in activity‑related symptoms and improved ROM can facilitate continued activity.
- Prolonged Collagen Peptide Supplementation and Resistance Exercise Training Affects Body Composition in Recreationally Active Men
PubMed ID: 31126103
Collagen peptide supplementation plus resistance training increased fat‑free mass in active men, supporting maintenance of physical activity capacity (not type‑II specific).
- Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women
PubMed ID: 29497287
Eggshell membrane improved recovery and reduced post‑exercise stiffness/pain in older women, facilitating low‑impact exercise participation.
- Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
PubMed ID: 17009253
Functional/pain improvements in knee OA patients suggest potential to support activity by reducing symptoms and improving function.
- Effects of oral administration of type II collagen on rheumatoid arthritis
PubMed ID: 8378772
Symptomatic improvement in some patients could enable greater participation in activity for responders.
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study
PubMed ID: 26822714
UC‑II improved pain and function which can enable greater participation in active pursuits.
- Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
PubMed ID: 26604721
Improvements in walking speed and knee-extensor strength support ability to maintain low-impact active lifestyles in trial subgroups.
Workout performance (9)
- Effects of oral administration of type II collagen on rheumatoid arthritis
PubMed ID: 8378772
Clinical improvements and remissions in some patients are likely to translate to better physical performance in responders.
- Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study
PubMed ID: 39719905
Improvements in 6MWT and balance tests indicate measurable physical performance gains with a supplement containing type‑II collagen.
- Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions
PubMed ID: 36918892
EC‑HC‑II group increased fat‑free mass and grip strength versus control, supporting improved performance.
- Efficacy and Safety of Dietary Undenatured Type II Collagen on Joint and Motor Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
PubMed ID: 35512781
NEXT‑II improved objective motor tests (walk, stair‑climb), indicating better physical performance.
- Prolonged Collagen Peptide Supplementation and Resistance Exercise Training Affects Body Composition in Recreationally Active Men
PubMed ID: 31126103
Collagen peptides plus resistance training increased fat‑free mass in recreationally active men, which can support performance outcomes.
- Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
PubMed ID: 17009253
Functional improvements in OA (Lequesne) reflect better physical performance in knee‑related tasks.
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Large symptomatic improvements are likely to translate to better physical performance in OA subjects.
- Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
PubMed ID: 26604721
Demonstrated increases in walking speed and knee-extensor strength in some subgroups — direct evidence for improved physical performance.
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
Objective gait improvements (peak vertical force/impulse) indicate better physical performance in arthritic dogs after UC‑II.
Illness recovery (7)
- Effects of oral administration of type II collagen on rheumatoid arthritis
PubMed ID: 8378772
Reports of remissions and reduction in joint counts suggest potential to accelerate clinical improvement in some RA patients.
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
UC‑II improved gait metrics over 150 days in arthritic dogs, implying faster return to better function vs baseline.
- Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study
PubMed ID: 39719905
Multi‑ingredient product with type‑II hydrolyzed collagen improved functional tests (6MWT, BBS) in 8 weeks, suggesting faster functional recovery.
- Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions
PubMed ID: 36918892
HC‑II produced early pain improvements by day 14, suggesting faster symptomatic improvement post‑intervention.
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
Type‑II collagen RCT produced faster symptomatic improvement vs placebo over 4–8 weeks (clinical recovery from baseline symptoms).
- Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women
PubMed ID: 29497287
Eggshell membrane reduced exercise‑induced CTX‑II and improved recovery from exercise‑related pain/stiffness within 2 weeks.
- Pressure ulcer healing with a concentrated, fortified, collagen protein hydrolysate supplement: a randomized controlled trial
PubMed ID: 16557055
Oral concentrated collagen hydrolysate accelerated pressure‑ulcer healing vs placebo — direct evidence of faster tissue recovery.
Muscle soreness (6)
- The effect of supplementation with type I and type III collagen peptide and type II hydrolyzed collagen on pain, quality of life and physical function in patients with meniscopathy: a randomized, double-blind, placebo-controlled study
PubMed ID: 39755603
Pain reductions in meniscopathy trial likely reduce post‑activity soreness.
- Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
PubMed ID: 38235711
Large symptomatic improvement and decreased CTX‑II suggest less cartilage‑related post‑activity soreness.
- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort
PubMed ID: 34371963
Type‑II collagen RCT reduced overall pain and may reduce post‑activity soreness though not specifically measured.
- Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women
PubMed ID: 29497287
Eggshell membrane reduced exercise‑induced cartilage degradation marker and improved 12‑hour recovery pain and stiffness; direct evidence for less post‑activity soreness.
- Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
PubMed ID: 26604721
Symptom/function improvements (JKOM) suggest reduced pain/soreness in some; specific post-activity soreness not directly measured.
- Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate
PubMed ID: 21623931
Reduced pain and improved gait can manifest as less soreness after activity in treated dogs; suggests similar potential in humans.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Type-II Collagen
Search all873 products whose verified label declares Type-II Collagen — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.